GenFleet Therapeutics Announces FDA's Clinical Trial Approval for GFH925 (KRAS G12C Inhibitor) Monotherapy in Phase III Registrational Study Treating Metastatic Colorectal Cancer
/PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announced US Food...
Yu Wang International Journal Of Molecular Science Drug Administration China National Medical Products Administration Fleet Therapeutics Breakthrough Therapy Designation
Source: prnewswire.com